Compare Dow Jones Industrial Average ETF (DIA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs TG Therapeutics Inc — how do they compare? Dow Jones Industrial Average ETF trades at $516.69 (market cap $45.20B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: Dow Jones Industrial Average ETF is far larger — about 5.5× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Dow Jones Industrial Average ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 104 Days and TG Therapeutics Inc for 16 Days on average.
| DIA | TGTX | |
|---|---|---|
Market Cap | $45.20B | $8.16B |
Volume | 4,095,368 | 1,735,121 |
52-Week High | $542.79 | $59.06 |
52-Week Low | $451.37 | $26.94 |
Typical Hold Time | 104 Days | 16 Days |
Sector | — | Health |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $515.82, up 0.94% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings with RSI at 46.24, while recent dividend distributions provide income appeal. Support levels cluster around $507-510 with resistance at $513-516.
Market sentiment reflects cautious optimism amid economic uncertainty, with institutional focus on Fed policy and earnings resilience. Key risks include interest rate sensitivity and market volatility, though the ETF's diversified Dow Jones exposure offers defensive characteristics in turbulent markets.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
